BRAF and melanoma: The outcome of the study of Lunavat et al. leads to better understanding of possible mechanisms of acquiring by patients’ resistance to the BRAF inhibitors treatment by showing that miR-211-5p can reduce the sensitivity to vemurafenib treatment in melanoma cells by regulating cellular proliferation.